Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders

10.1046/j.1365-2516.2003.00711.x

10.1111/j.1365-2141.1993.tb03065.x

Santagostino E, 1994, Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery, Thromb Haemost, 71, 737, 10.1055/s-0038-1642515

10.1111/j.1365-2141.2006.06087.x

10.1111/j.1365-2516.2004.00886.x

10.1111/j.1365-2516.2004.00944.x

10.1016/S0037-1963(01)90104-0

Lee CA, 1996, Bailliere’s Clinical Haematology, 369

10.1182/asheducation-2005.1.429

10.1111/j.1365-2141.2006.06343.x

10.1111/j.1365-2141.2004.04988.x

10.1046/j.1365-2516.2002.00678.x

Rodeghiero F, 1996, Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A, Thromb Haemost, 76, 692, 10.1055/s-0038-1650645

10.1182/blood-2004-11-4472

10.1111/j.1365-2516.2006.01314.x

10.1016/j.thromres.2006.09.004

10.1002/14651858.CD001886.pub2

10.1097/00000542-200611000-00026

10.1056/NEJMra040403

10.1023/A:1025013213192

10.1111/j.1601-0825.2005.01111.x

10.1016/0140-6736(93)90044-H

10.1053/tm.2001.25376

Note for guidance on plasma derived medicinal products.: Committee for Proprietary Medicinal Products (CPMP). Document number CPMP/BWP/269/95 rev 3 2001.

10.1046/j.1365-2141.2002.03293.x

10.1016/S0140-6736(94)91878-3

10.1055/s-2006-946908

2007, Fourth case of transfusion‐associated vCJD infection in the United Kingdom, Euro Surveill, 12, E070118

10.1016/j.tracli.2006.11.006

10.1016/0140-6736(92)90874-3

10.1046/j.1365-2516.1999.00300.x

10.1055/s-0038-1655911

10.1055/s-0038-1651565

10.1182/blood-2005-04-1371

10.1182/blood-2006-11-056317

10.1111/j.1365-2516.2006.01373.x

10.1002/9780470757260.ch14

De Biasi R, 1991, The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus‐infected hemophiliacs: a randomized, prospective, two‐year comparison with an intermediate purity concentrate, Blood, 78, 1919, 10.1182/blood.V78.8.1919.1919

10.1016/S0140-6736(94)92345-0

10.1016/S0140-6736(94)92237-3

10.1046/j.1365-2141.1997.d01-2015.x

10.1055/s-0037-1613227

10.1182/blood.V99.2.450

10.1111/j.1538-7836.2004.00944.x

10.1056/NEJM198801143180215

10.1016/0140-6736(90)92623-P

10.1002/14651858.CD001884.pub2

10.1056/NEJM199807233390407

10.1056/NEJM198310063091402